Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).
ResMed Inc has announced a change in beneficial ownership as reported by Nicole Mowad-Nassar, a director and 10% owner of the company. The transaction involved the acquisition of 536 shares of ResMed common stock, which were awarded as Restricted Stock Units (RSUs) set to vest in full by November 2026 or at the next annual meeting of stockholders. This move signifies a potential increase in insider confidence and may impact stakeholder perceptions positively, reflecting ongoing commitment to the company’s growth and stability.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc operates in the healthcare industry, primarily focusing on the development and manufacturing of products for the treatment of sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. The company is known for its innovative solutions and devices that enhance the quality of life for patients with respiratory disorders.
Average Trading Volume: 1,214,271
Technical Sentiment Signal: Buy
Current Market Cap: A$56.69B
For an in-depth examination of RMD stock, go to TipRanks’ Overview page.